Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice

FEMS Immunology and Medical Microbiology

Volumn 63, Issue 3, 2011, Pages 407-417

  Hirano, Takashi ^a   Kodama, Satoru ^a   Kawano, Toshiaki ^a   Maeda, Kazuhiko ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Monophosphoryl lipid A; Moraxella catarrhalis; Nontypeable Haemophilus influenzae; Toll like receptor 4

Indexed keywords

CD11B ANTIGEN; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HISTOPATHOLOGY; INFLAMMATORY CELL; INNATE IMMUNITY; INOCULATION; MORAXELLA CATARRHALIS; MOUSE; NASOPHARYNX; NEUTROPHIL; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BACTERIAL LOAD; HAEMOPHILUS INFLUENZAE; IMMUNITY, INNATE; LIPID A; MICE; MICE, INBRED BALB C; MORAXELLA (BRANHAMELLA) CATARRHALIS; NASOPHARYNX; TIME FACTORS; TOLL-LIKE RECEPTOR 4;

EID: 80755126966     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00866.x     Document Type: Article

References (25)

1. Baldrick P, Richardson D, Elliot G & Wheeler W (2002) Safety evaluation of monophosphoryl lipid A: an immunostimulatory adjuvant. Regul Toxicol Pharmacol 35: 398-413.
2. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D & Persing D (2004) Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4: 1129-1138.
3. Berman S (1995) Otitis media in children. N Engl J Med 332: 1560-1565.
4. Brook I & Gober AE (1998) Microbiologic characteristics of persistent otitis media. Arch Otolaryngol Head Neck Surg 124: 1350-1352.
5. Casella CR & Mitchell TC (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65: 20.
6. Clement G, Evans SE, Evans CM et al. (2008) Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 177: 1322-1330.
7. Commisso R, Romero-Orellano F, Montanaro PB, Romero-Moroni F & Romero-Diat R (2000) Acute otitis media: bacteriology and bacterial resistance in 205 pediatric patients. Int J Pediatr Otorhinolaryngol 56: 23-31.
8. Dupont J, Altclas J, Lepetic A et al. (2006) A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 24: 7167-7174.
9. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DJ & Baldridge JR (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2: 219-229.
10. Falk P, Borén T, Haslam D & Caparon M (1994) Bacterial adhesion and colonization assays. Methods Cell Biol 45: 165-192.
11. Halfhide CP, Brearey SB, Flanagan BF et al. (2009) Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Thorax 64: 798-805.
12. Hirano T, Hou Y, Jiao X & Gu XX (2003) Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol Med Microbiol 35: 1-10.
13. Hirano T, Kodama S, Fujita K, Maeda K & Suzuki M (2007) Role of Toll-like receptor 4 in innate immune responses in a mouse model of acute otitis media. FEMS Immunol Med Microbiol 49: 75-83.
14. Holmgren J & Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-S53.
15. Kanzler H, Barrat FJ, Hessel EM & Coffman RL (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559.
16. Kodama S, Suenaga S, Hirano T, Suzuki M & Mogi G (2000) Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun 68: 2294-3000.
17. Kurono Y, Yamamoto M, Fujihashi K et al. (1999) Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J Infect Dis 1180: 122-132.
18. Lembo A, Pelletier M, Iyer R et al. (2008) Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 180: 7574-7581.
19. -ΔΔCT method. Methods 25: 402-408.
20. Parker D & Prince A (2011) Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 45: 189-201.
21. Ragnarsdóttir B, Samuelsson M, Gustafsson MC, Leijonhufvud I, Karpman D & Svanborg C (2007) Reduced Toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 196: 475-484.
22. Sabirov A, Kodama S, Hirano T, Suzuki M & Mogi G (2001) Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 69: 2964-2971.
23. Takeda K, Kaisho T & Akira S (2003) Toll-like receptors. Annu Rev Immunol 21: 335-376.
24. Wang X, Moser C, Louboutin JP et al. (2002) Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. J Immunol 168: 810-815.
25. Yu FS, Cornicelli MD, Kovach MA et al. (2010) Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 185: 1142-1149.